1.99 USD
-0.07 (-3.4%)
We assign a fundamental rating of 4 out of 10 to VIVS. VIVS was compared to 525 industry peers in the Biotechnology industry. The financial health of VIVS is average, but there are quite some concerns on its profitability. VIVS is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- VIVS had positive earnings in the past year.
- In the past year VIVS has reported a negative cash flow from operations.
- VIVS had negative earnings in each of the past 5 years.
- VIVS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- VIVS has a Return On Assets of -20.47%. This is in the better half of the industry: VIVS outperforms 76.00% of its industry peers.
- Looking at the Return On Equity, with a value of -28.07%, VIVS is in the better half of the industry, outperforming 77.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.47% | ||
| ROE | -28.07% | ||
| ROIC | N/A |
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VIVS has a better Gross Margin (98.57%) than 97.90% of its industry peers.
- In the last couple of years the Gross Margin of VIVS has grown nicely.
- VIVS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
2. Health
2.1 Basic Checks
- VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VIVS has less shares outstanding than it did 1 year ago.
- VIVS has less shares outstanding than it did 5 years ago.
- There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -52.50, we must say that VIVS is in the distress zone and has some risk of bankruptcy.
- VIVS has a worse Altman-Z score (-52.50) than 90.48% of its industry peers.
- VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -52.5 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- VIVS has a Current Ratio of 3.10. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
- VIVS's Current ratio of 3.10 is on the low side compared to the rest of the industry. VIVS is outperformed by 63.05% of its industry peers.
- VIVS has a Quick Ratio of 3.10. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
- VIVS has a worse Quick ratio (3.10) than 60.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.1 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- VIVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 278.71%, which is quite impressive.
- Looking at the last year, VIVS shows a very strong growth in Revenue. The Revenue has grown by 35.92%.
- VIVS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.03% yearly.
EPS 1Y (TTM)278.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-589.48%
Revenue 1Y (TTM)35.92%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-6.67%
3.2 Future
- Based on estimates for the next years, VIVS will show a decrease in Earnings Per Share. The EPS will decrease by -6.30% on average per year.
- Based on estimates for the next years, VIVS will show a quite strong growth in Revenue. The Revenue will grow by 16.82% on average per year.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- VIVS is valuated cheaply with a Price/Earnings ratio of 1.04.
- Based on the Price/Earnings ratio, VIVS is valued cheaper than 99.81% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.94, VIVS is valued rather cheaply.
- VIVS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.04 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- VIVS's earnings are expected to decrease with -6.30% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for VIVS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:VIVS (1/21/2026, 4:10:13 PM)
1.99
-0.07 (-3.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)06-03 2026-06-03/bmo
Inst Owners8.59%
Inst Owner ChangeN/A
Ins Owners0.6%
Ins Owner ChangeN/A
Market Cap5.19M
Revenue(TTM)140.00K
Net Income(TTM)-1.98M
Analysts45.71
Price TargetN/A
Short Float %0.43%
Short Ratio0.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.96%
Min Revenue beat(2)-45.1%
Max Revenue beat(2)-22.82%
Revenue beat(4)1
Avg Revenue beat(4)-26.44%
Min Revenue beat(4)-46.52%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-32.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.04 | ||
| Fwd PE | N/A | ||
| P/S | 37.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.74 | ||
| P/tB | 0.74 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.91
EY95.98%
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-3.89
FCFYN/A
OCF(TTM)-3.89
OCFYN/A
SpS0.05
BVpS2.71
TBVpS2.71
PEG (NY)0.4
PEG (5Y)N/A
Graham Number10.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.47% | ||
| ROE | -28.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.57% | ||
| FCFM | N/A |
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.1 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | -52.5 |
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)278.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-589.48%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)35.92%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-6.67%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.48%
OCF growth 3YN/A
OCF growth 5YN/A
VIVOSIM LABS INC / VIVS FAQ
What is the ChartMill fundamental rating of VIVOSIM LABS INC (VIVS) stock?
ChartMill assigns a fundamental rating of 4 / 10 to VIVS.
Can you provide the valuation status for VIVOSIM LABS INC?
ChartMill assigns a valuation rating of 4 / 10 to VIVOSIM LABS INC (VIVS). This can be considered as Fairly Valued.
What is the profitability of VIVS stock?
VIVOSIM LABS INC (VIVS) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for VIVS stock?
The Price/Earnings (PE) ratio for VIVOSIM LABS INC (VIVS) is 1.04 and the Price/Book (PB) ratio is 0.74.
What is the expected EPS growth for VIVOSIM LABS INC (VIVS) stock?
The Earnings per Share (EPS) of VIVOSIM LABS INC (VIVS) is expected to grow by 2.6% in the next year.